• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PUROMYCIN Drug Record

  • Summary
  • Interactions
  • Claims
  • PUROMYCIN chembl:CHEMBL469912 Antineoplastic

    Alternate Names:

    CL-13900
    P-638
    3123L
    TCMDC-123493
    GNF-PF-2016
    PUROMYCIN

    Drug Info:

    (0 More Sources)

    Publications:

    Marvizon et al., 2003, Effect of peptidases on the ability of exogenous and endogenous neurokinins to produce neurokinin 1 receptor internalization in the rat spinal cord., Br. J. Pharmacol.
    Mizokuchi et al., 1992, Possible mechanism of impaired calcium and vitamin D metabolism in nephrotic rats., Kidney Int.
    Ma et al., 2000, [Effect of mouse p53 minigene on lung cancer cells with different 172 structures regulated by tetracycline]., Zhonghua Bing Li Xue Za Zhi
    Ghosh et al., 2002, The role of the renin-angiotensin system in cholesterol and puromycin mediated renal injury., Am. J. Med. Sci.
    Lee et al., 1987, Effect of cycloheximide or puromycin on induction of thermotolerance by heat in Chinese hamster ovary cells: dose fractionation at 45.5 degrees C1., Cancer Res.
    Theodorakis et al., 1988, HSP70 mRNA translation in chicken reticulocytes is regulated at the level of elongation., J. Biol. Chem.
    Hayashi et al., 1991, Translocation of hsp-70 and protein synthesis during continuous heating at mild temperatures in HeLa cells., Radiat. Res.
    Indraccolo et al., 1993, Standardization of in vitro synthesis and detection of HIV-1-specific antibodies., J. Immunol. Methods
    Marchetti et al., 2002, Endothelial cells genetically selected from differentiating mouse embryonic stem cells incorporate at sites of neovascularization in vivo., J. Cell. Sci.
  • PUROMYCIN   CD34

    Interaction Score: 3.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11973349


    Sources:
    NCI

  • PUROMYCIN   AGTR2

    Interaction Score: 2.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12495295


    Sources:
    NCI

  • PUROMYCIN   HSPA4

    Interaction Score: 1.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3664499 3170555 1986403


    Sources:
    NCI

  • PUROMYCIN   PTH

    Interaction Score: 0.91

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1328752


    Sources:
    NCI

  • PUROMYCIN   FCGR3B

    Interaction Score: 0.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8423352


    Sources:
    NCI

  • PUROMYCIN   TAC1

    Interaction Score: 0.7

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14623771


    Sources:
    NCI

  • PUROMYCIN   FCGR3A

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8423352


    Sources:
    NCI

  • PUROMYCIN   TP53

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11866936


    Sources:
    NCI

  • NCI: PUROMYCIN

    • Version: 14-September-2017

    Alternate Names:
    C787 NCI drug code

    Drug Info:

    Publications:
    Marvizon et al., 2003, Effect of peptidases on the ability of exogenous and endogenous neurokinins to produce neurokinin 1 receptor internalization in the rat spinal cord., Br. J. Pharmacol.
    Indraccolo et al., 1993, Standardization of in vitro synthesis and detection of HIV-1-specific antibodies., J. Immunol. Methods
    Ma et al., 2000, [Effect of mouse p53 minigene on lung cancer cells with different 172 structures regulated by tetracycline]., Zhonghua Bing Li Xue Za Zhi

  • ChemblDrugs: chembl:CHEMBL469912

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21